Profile data is unavailable for this security.
About the company
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
- Revenue in USD (TTM)409.00k
- Net income in USD-101.35m
- Incorporated2005
- Employees59.00
- LocationAltimmune Inc910 Clopper Road, Suite 201SGAITHERSBURG 20878-1361United StatesUSA
- Phone+1 (240) 654-1450
- Fax+1 (302) 674-5266
- Websitehttps://altimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absci Corp | 3.25m | -92.26m | 486.02m | 155.00 | -- | 2.19 | -- | 149.55 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -31.45m | 498.54m | 31.00 | -- | 2.29 | -- | -- | -1.24 | -1.24 | 0.00 | 8.46 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 515.90m | 116.00 | -- | -- | -- | 20.22 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 522.37m | 59.00 | -- | 3.42 | -- | 1,277.19 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Prime Medicine Inc | 591.00k | -217.44m | 526.94m | 234.00 | -- | 2.68 | -- | 891.60 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Chromadex Corp | 91.67m | 1.49m | 535.45m | 106.00 | 370.31 | 15.51 | 230.20 | 5.84 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Kezar Life Sciences Inc | 7.00m | -98.57m | 542.84m | 58.00 | -- | 0.3599 | -- | 77.55 | -13.55 | -13.55 | 0.962 | 20.67 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Verve Therapeutics Inc | 24.40m | -197.03m | 543.54m | 255.00 | -- | 1.07 | -- | 22.28 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 543.55m | 106.00 | -- | 1.85 | -- | 25.03 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 544.32m | 150.00 | -- | 2.76 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| MeiraGTx Holdings PLC | 8.12m | -93.14m | 548.01m | 387.00 | -- | 5.74 | -- | 67.47 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Q32 Bio Inc | 0.00 | -49.66m | 548.25m | 42.00 | -- | 29.86 | -- | -- | -7.44 | -7.44 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -27.86 | -34.98 | -33.25 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.4079 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 550.85m | 180.00 | -- | 2.11 | -- | 3.43 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Aura Biosciences Inc | 0.00 | -80.69m | 552.61m | 88.00 | -- | 2.89 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Altimmune Inc's reporting currency: US Dollar USD
35.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.87m | 6.86% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.74m | 6.67% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.41m | 4.80% |
| Threadneedle Asset Management Ltd.as of 30 Jun 2024 | 3.08m | 4.33% |
| Tang Capital Management LLCas of 30 Jun 2024 | 2.75m | 3.87% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 2.21m | 3.11% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.59m | 2.24% |
| Knoll Capital Management LPas of 30 Jun 2024 | 1.12m | 1.58% |
| Capital Fund Management SAas of 30 Jun 2024 | 886.28k | 1.25% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 762.36k | 1.07% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
